CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
PF-04958242 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02228395
NCT02228395Phase 1Completed

A Phase 1, Randomized, Subject- And Investigator-blind, Sponsor Open, Placebo Controlled, Single Ascending Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-04958242 Following Oral Dose Capsules in Healthy Subjects

Biogen·interventional·Posted Aug 29, 2014·Updated Jan 7, 2020

In Brief

A Phase 1 clinical trial evaluating PF-04958242 and Placebo for Healthy. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of single ascending doses in healthy volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 29, 2014
Enrollment StartSep 22, 2014
Primary CompletionNov 13, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.8 years ago

Interventions

PF-04958242drug

Administered as specified in treatment arm

Placebodrug

Administered as specified in treatment arm